Today's Hours: 8:00am - 10:00pm

Search

Did You Mean:

Search Results

  • Book
    David Green.
    Summary: Hemophilia and Von Willebrand Disease: Factor VIII and Von Willebrand Factor serves as a must-have reference on the important role these essential blood-clotting proteins play in research and clinical medicine. Clinicians and researchers face the daily challenge of staying current on the vast amounts of research that is now generated. The reference to Janus in the title refers to the two roles of the Factor VIII/Von Willebrand Factor Complex: initiation of coagulation and propagation of clot formation. The complex prevents bleeding in hemophilia and Von Willebrand disease but also augments arterial and venous thrombosis. Presents one source of information on Hemophilia and Von Willebrand Disease, as well as Factor VIII and Von Willebrand Factor, eliminating the search through hundreds of journal articles.
    Digital Access ScienceDirect 2018
  • Article
    Terezhalmy GT, Bottomley WK, Pelleu GB.
    Oral Surg Oral Med Oral Pathol. 1978 Jan;45(1):56-62.
    The efficacy of a water-soluble bioflavonoid-ascorbic acid complex was evaluated in the treatment of fifty episodes of recurrent herpes labialis. Twenty episodes were treated with a complex of 600 mg. of water-soluble bioflavonoids and 600 mg. of ascorbic acid, administered in equal increments three times daily. Twenty episodes were treated with a complex of 1,000 mg. of water-soluble bioflavonoids and 1,000 mg. of ascorbic acid, administered in equal increments five times daily. Ten episodes were treated with a lactose placebo. The therapeutic regimen was maintained for 3 days after the recognition of the initial symptoms associated with recurrent herpes labialis. The water-soluble bioflavonoid-ascorbic acid complex was observed to reduce vesiculation and to prevent the disruption of the vesicular membrane. The therapeutic measure was found to be most effective when initiated during the prodomal stage of the disease process. Optimum remission of symptoms was observed in 4.2 +/- 1.7 days with the 600 mg. dosage of the water-soluble bioflavonoid-ascorbic acid complex. No adverse reactions were reported by any of the patients who participated in this investigation.
    Digital Access Access Options